| 產(chǎn)品編號 | bs-10103R-Gold |
| 英文名稱1 | Rabbit Anti-SIGLEC7/Gold Conjugated antibody |
| 中文名稱 | 膠體金標(biāo)記的唾液酸結(jié)合性免疫球蛋白樣凝集素7抗體 |
| 別 名 | Sialic Acid Binding Ig-Like Lectin 7; AIRM1; QA79 Membrane Protein; SIGLEC-7; D-Siglec; AIRM-1; CDw328; P75; Sialic Acid Binding Ig-Like Lectin 19, Pseudogene; Adhesion Inhibitory Receptor Molecule 1, Siglec-7; Sialic Acid Binding Ig-Like Lectin, Pseudogene 2; Sialic Acid Binding Immunoglobulin-Like Lectin 7; Adhesion Inhibitory Receptor Molecule 1; Sialic Acid-Binding Ig-Like Lectin 7; CD328 Antigen; P75/AIRM1; SIGLEC19P; SIGLECP2; CD328; QA79; SIGL7_HUMAN; |
| 規(guī)格價(jià)格 | 100ul/2980元 購買 大包裝/詢價(jià) |
| 說 明 書 | 100ul（10nm 15nm 35nm） |
| 研究領(lǐng)域 | 腫瘤 心血管 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 干細(xì)胞 細(xì)胞表面分子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, ) |
| 產(chǎn)品應(yīng)用 | IEM=1:20-200 ICA=1:20-200 ChIP=1:20-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 51kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 0.4mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human SIGLEC7 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.02M TBS(pH8.2) with 1% BSA, 0.03% Proclin300. |
| 保存條件 | Store at 2-8 oC for 3-6 months. Avoid repeated freeze/thaw cycles. |
| 產(chǎn)品介紹 |
background: Siglec 7 is a member of the Siglec (sialic acid-binding immunoglobulin like lectin) subgroup of the immunoglobulin superfamily. Siglec 7 is able to mediate high levels of sialic acid-dependent binding to human erythrocytes and soluble sialoglycoconjugates. Addition of anti-Siglec 7 to haematopoietic cell cultures leads to reduced cell growth and prevents the development of dendritic cells. Predominantly expressed by resting and activated natural killer cells and at lower levels by granulocytes and monocytes. High expression can be found in tissues like the placenta, liver, lung, spleen, and peripheral blood leukocytes. Function: Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Preferentially binds to alpha-2,3- and alpha-2,6-linked sialic acid. Also binds disialogangliosides (disialogalactosyl globoside, disialyl lactotetraosylceramide and disialyl GalNAc lactotetraoslylceramide). The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. Mediates inhibition of natural killer cells cytotoxicity. May play a role in hemopoiesis. Inhibits differentiation of CD34+ cell precursors towards myelomonocytic cell lineage and proliferation of leukemic myeloid cells (in vitro). Subcellular Location: Membrane; Single-pass type I membrane protein Tissue Specificity: Predominantly expressed by resting and activated natural killer cells and at lower levels by granulocytes and monocytes. High expression found in placenta, liver, lung, spleen, and peripheral blood leukocytes. Post-translational modifications: Tyrosine phosphorylated. Similarity: Belongs to the immunoglobulin superfamily. SIGLEC (sialic acid binding Ig-like lectin) family. Contains 2 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 Ig-like V-type (immunoglobulin-like) domain. Database links: Entrez Gene: 27036 Human Omim: 604410 Human SwissProt: Q9Y286 Human Unigene: 274470 Human Unigene: 655393 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
